Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche and Genentech pay milestone fee to ForSight Vision4

Roche and Genentech pay milestone fee to ForSight Vision4

16th January 2012

Roche and Genentech have made their first milestone payment to ForSight Vision4 in their partnership to create a new drug delivery device for Lucentis.

The fee was triggered following Genentech's decision to submit an investigational new drug application for clinical testing of the device – a refillable drug port delivery system that releases Lucentis over a period of months – in the US.

Genentech, Roche and ForSight Vision4 have been working to develop the proprietary implantable ocular device since the agreement of an exclusive licence deal in December 2010.

The arrangement also provides Genentech with the option to apply the device to other selected targets for treating ophthalmic diseases.

Dr Hal Barron, chief medical officer and head of global product development at Roche, said: "This development reflects Genentech's commitment to ophthalmology and investigating new technologies that may potentially provide sustained delivery of Lucentis and reduce the frequency of injections."

Earlier this month, Roche subsidiary Genentech agreed a new drug discovery collaboration with Vernalis, utilising an innovative fragment and structure-based drug discovery platform.ADNFCR-8000103-ID-801265096-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.